Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Abstract 5538: Direct inhibition of ERK1/2 by VTX-11e leads to increased induction of apoptosis in a subset of pancreatic cancer cell lines as compared to MEK1/2 inhibition by selumetinib (AZD6244).2013 · 5 citations
2. 2Integrating signals from RTKs to ERK/MAPK2007 · 623 citations
3. 3Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)2013 · 187 citations
4. 4Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group2012 · 1,342 citations
5. 5Phosphorylated Extracellular Signal-regulated Kinases Are Significantly Increased in Malignant Mesothelioma2006 · 33 citations